Reversible inhibitor of vesicular trafficking between endoplasmic reticulum and Golgi apparatus. Modifies Golgi ADP-ribosylation factor (ARF)1 GTPase activity and inhibits exocytosis (IC50 ~ 20 mM). Has similar, but not identical, action to brefeldin A (Cat. No. 1231).
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|ethanol||6.83||25mM with gentle warming|
Preparing Stock Solutions
The following data is based on the product molecular weight 273.26. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.66 mL||18.3 mL||36.6 mL|
|5 mM||0.73 mL||3.66 mL||7.32 mL|
|10 mM||0.37 mL||1.83 mL||3.66 mL|
|50 mM||0.07 mL||0.37 mL||0.73 mL|
References are publications that support the products' biological activity.
Feng et al (2003) Exo1: A new chemical inhibitor of the exocytic pathway. Proc.Natl.Acad.Sci.U.S.A. 100 6469 PMID: 12738886
If you know of a relevant reference for Exo1, please let us know.
Keywords: Exo1, supplier, inhibitors, inhibits, Golgi-ER, traffic, blocks, exocytosis, Golgi, ADP-ribosylation, factor, ARF1, GTPase, Translocation,, Exocytosis, &, Endocytosis, Translocation,, Exocytosis, &, Endocytosis, Tocris Bioscience
1 Citation for Exo1
Citations are publications that use Tocris products. Selected citations for Exo1 include:
Greene et al (2017) XE991 and Linopirdine are state-dependent inhibitors for Kv7/KCNQ channels that favor activated single subunits. J.Pharmacol.Exp.Ther. 362 177 PMID: 28483800
Do you know of a great paper that uses Exo1 from Tocris? If so please let us know.
Average Rating:(Based on 0 Reviews)